-
The FDA has approved a new intravenous antifungal agent.
-
Patients with an effective regurgitant orifice of at least 40 mm2 should promptly be considered for cardiac surgery.
-
There has been enormous controversy regarding the benefit/safety relationship of the COX-2 inhibitors, which were initially introduced in 1999. This is a cautionary tale.
-
Concealed renal insufficiency is common and contributes to adverse drug reactions from hydrosoluble medications.
-
-
Nesiritide, Scios' intravenous recombinant form of human B-type naturetic peptide, has been widely used for the treatment of congestive heart failure in hospitalized patients. That may change with the publication of a new study that suggests that patients with acutely decompensated heart failure treated with nesiritide have a higher death rate at 30 days compared with patients who are not treated with the drug.
-
The lead II rhythm strip shown in the Figure was obtained from an older man with ischemic cardiomyopathy. This asymptomatic 10-beat run of anomalous complexes was felt to be too irregular for VT (ventricular tachycardia). Do you agree?
-
Because many of the clinical consequences of hemochromatosis are able to be reversed, or at least halted by appropriate treatment (phlebotomy), it is important to heighten clinician awareness of the disorder.
-
La Puma J. Adverse reactions associated with echinacea use. Altern Med Alert 2002;5(9):112.
-